Which information should be given to the patient concerning the cardiovascular and renal risk of the NSAIDs?

被引:0
|
作者
Flipo, Rene-Marc [1 ]
Heloire, Francois
Deray, Gilbert
机构
[1] CHU Roger Salengro, Serv Rhumatol, F-59000 Lille, France
[2] CHU Pitie Salpetriere, Serv Nephrol, Paris, France
来源
PRESSE MEDICALE | 2006年 / 35卷 / 09期
关键词
D O I
10.1016/S0755-4982(06)74943-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective > Patient information is a topical subject. The aim of this review is to present the rare studies concerning the degree of patient information on the Cardiovascular and renal risks of the non-steroidal anti-inflammatory drugs and to suggest some recommendations on this subject. Methodology > After analysis of the literature (Medline search January 2006), a series of recommendations has been drown up following discussion among experts from different specialties (clinic of epidemiology rheumatology cardiology nephrology gastroenterology). Recommendations > It appears necessary to warn all patients of the potential risk of hyperkalemia, renal insufficiency and/or hydrosodium retention (decompensation of an arterial hypertension or a cardiac insufficiency), especially subjects who present risk factors such as age over 75 years, a dehydration, a pre-existing renal disorder, etc. Concerning the risk of arterial thrombotic incident (coronary or cerebral), it is important to indicate that this risk is rare and seems to be observed particularly during prolonged treatments and at high dose.
引用
收藏
页码:69 / 72
页数:4
相关论文
共 50 条
  • [1] Information which should be given to the patient
    Marabelle, B.
    Guex, J. -J.
    PHLEBOLOGIE-ANNALES VASCULAIRES, 2009, 62 (01): : 82 - 82
  • [2] Details of treatment which should be given to the patient before sclerotherapy of varices
    Marabelle, B.
    Guex, J. -J
    PHLEBOLOGIE-ANNALES VASCULAIRES, 2009, 62 (01): : 83 - 84
  • [3] Which cardiovascular risk tables should we use?
    Masana, Lluis
    REVISTA ESPANOLA DE CARDIOLOGIA, 2007, 60 (07): : 690 - 692
  • [4] Cardiovascular risk of the diabetic patient: which evidence?
    Bonnet, Fabrice
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2018, 202 (5-6): : 887 - 893
  • [5] What is the impact of cardiovascular and renal complications on the benefit/risk ratio of the NSAIDs?
    Chaussade, Stanislas
    Avouac, Bernard
    Vicaut, Eric
    PRESSE MEDICALE, 2006, 35 (09): : 61 - 68
  • [6] Cardiovascular risk in the renal transplanted patient
    Campistol, JM
    NEFROLOGIA, 2002, 22 : 7 - 11
  • [7] Cardiovascular risk in renal transplanted patient
    Campistol, JM
    NEFROLOGIA, 2002, 22 : 75 - 79
  • [8] Cardiovascular risk of the diabetic patient ; which evidence? DISCUSSION
    Battin, Jacques
    Godeau, Pierre
    Kahan, Andre
    Bousser, Marie-Germaine
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2018, 202 (5-6): : 894 - 895
  • [9] CARDIOVASCULAR RISK-FACTORS - WHICH ONES CAN AND SHOULD BE REMEDIED
    ELLIOTT, WJ
    POSTGRADUATE MEDICINE, 1994, 96 (03) : 49 - &
  • [10] Homocysteine or renal impairment - Which is the real cardiovascular risk factor?
    Potter, Kathleen
    Hankey, Graeme J.
    Green, Daniel J.
    Eikelboom, John W.
    Arnolda, Leonard F.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (06) : 1158 - 1164